

18 August 2015

ANP to Present at Canary Biotech and Healthcare Investor Roadshow

Antisense Therapeutics Ltd. (ASX:ANP) today announced that CEO and Managing Director, Mark Diamond, will present at the Canary Biotech and Healthcare Investor Roadshow in Melbourne on Wednesday 19th August.

About Canary Networks

Established in 2009, Canary Networks is a specialist investor and corporate communications business providing a unique platform for ASX listed companies to engage with the financial and investment communities. Attendees at their Investor Roadshows include fund managers, stockbrokers, retail investors, SMSFs and HNWs. Website: www.canarynetworks.com.au

Contact Information: Website: www.antisense.com.au
Managing Director: Mark Diamond +61 (3) 9827 8999

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. Its mission is to create, develop and commercialise second generation antisense pharmaceuticals for large unmet markets. Antisense Therapeutics has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals Inc. (ISIS), a world leader in antisense drug development and commercialisation - ATL1102 (injection) which has successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS), ATL1103 drug designed to block GHR production which in a Phase II clinical trial, successfully reduced blood IGF-1 levels in patients with the growth disorder acromegaly, ATL1102 (inhaled) which is at the pre-clinical research stage as a potential treatment for asthma and ATL1101 a second-generation antisense drug at the pre-clinical stage being investigated as a potential treatment for cancer.